Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 8/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 7/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5729362 | 0.93 | ADRA1A (0.47) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL5730355 | 0.91 | ADRA1A (0.44) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL5729295 | 0.89 | ADRA1A (0.42) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL5730983 | 0.89 | ADRA1A (0.45) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL5730482 | 0.86 | ADRA1A (0.48) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL5731220 | 0.85 | ADRA1A (0.47) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL5730673 | 0.83 | ADRA1A (0.44) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL5729745 | 0.83 | ADRA1A (0.45) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL5730989 | 0.83 | ADRA1A (0.47) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL5730669 | 0.80 | ADRA1A (0.42) | ADRA1AADRA1DADRA1BADRA2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501826-B1 | SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS | HOFFMANN LA ROCHE (CH) | 2006-09-27 | — | — | EP | disclosed |
| US-6852726-B2 | Substituted indoles as alpha-1 agonists | SYNTEX LLC (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1501826-A2 | SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS | F. Hoffman-la Roche AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20030220319-A1 | Substituted indoles as alpha-1 agonists | SYNTEX (U.S.A.) LLC | 2003-11-27 | — | — | US | disclosed |
| WO-2003064387-A2 | SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS | F. HOFFMAN-LA ROCHE AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220319-A1 | Substituted indoles as alpha-1 agonists | ADRA1A, ADRB1, ADRA1B | ADRA1A 1/4885ADRA1D 4/4885ADRA1B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.